DiagnaMed Holdings Corp. · CSE:DMED

DiagnaMed — Investor Presentation (November 2024)

19 slides from DiagnaMed's investor presentation, November 2024

  1. Slide 1: DiagnaMed Holdings Corp. Corporate Presentation

    DiagnaMed Holdings Corp. Corporate Presentation NOVEMBER 2024 CSE: DMED | OTCQB: DGNMF

  2. Slide 2: Summary

    Summary Focused on medical solutions for Brain Health +2 billion people with mental health and neurological disorders HydroPharm™, a patent-pending molecular hydrogen product BRAIN AGE® AI Brain Health Platform Growing commercial and clinical partnerships Multiple value-creating milestones in 2025 D

  3. Slide 3: Brain Health Market

    Brain Health Market +1 Billion +1 Billon Mental Health Neurodegenerative DiagnaMed CSE: DMED | OTCQB: DGNMF

  4. Slide 4: Unlocking the medical potential of Hydrogen

    Unlocking the medical potential of Hydrogen DiagnaMed CSE: DMED | OTCQB: DGNMF

  5. Slide 5: Molecular Hydrogen

    Molecular Hydrogen Molecular hydrogen therapy is a rapidly growing field and poised for clinical adoption Over 2,000 scientific publications on potential therapeutic effects in over 100 human studies Clinically demonstrated to provide antioxidant, anti- inflammatory and neuroprotective effects Poten

  6. Slide 6: Potential Medical Uses of Hydrogen

    Potential Medical Uses of Hydrogen Current Focus Brain Dementia Parkinson’s disease Depression Alzheimer’s disease TBI/Concussions Stroke Stroke Aging Ischemia/reperfusion injuries Inflammation Metabolic Syndrome Side effects by cancer drugs Organ Transplants Sepsis Diabetes Radiotherapy Post-cardia

  7. Slide 7: Clinical Validation

    Clinical Validation DiagnaMed CSE: DMED | OTCQB: DGNMF

  8. Slide 8: Limitations of Molecular Hydrogen

    Limitations of Molecular Hydrogen Clinical use is limited primarily due to its: Low hydrogen content Rapid evaporating action in water Lower effective concentration and poor stability Hydrogen inhalation and hydrogen-rich water machines are: Expensive, bulky and complex to use Challenging to determi

  9. Slide 9: Solution for Molecular Hydrogen

    Solution for Molecular Hydrogen Developing novel oral molecular hydrogen therapy specifically tailored for neurological disorders Offering different doses, durations, and methods of administration Partner with companies that have or are exploring ‘white’ hydrogen sources Hydrogen gas for medical use

  10. Slide 10: Utilizing AI for Brain Health

    Utilizing AI for Brain Health DiagnaMed CSE: DMED | OTCQB: DGNMF

  11. Slide 11: Estimating BRAIN AGE

    B R A I N A G E A I ® Estimating BR AIN AGE® Providing Brain Health Risk Score Monitoring Overall Brain Health DiagnaMed CSE: DMED | OTCQB: DGNMF

  12. Slide 12: Clinical Validation

    Clinical Validation DiagnaMed CSE: DMED | OTCQB: DGNMF

  13. Slide 13: Features

    Features Brain Age Brain Health 1 2 Estimation Risk Score Use of novel EEG Evaluate overall device and ML/AI brain health risk techniques for score, and provide predicting and actionable data. monitoring brain age. BR A IN AGE® 4 Brain Health 3 Brain Health Maintenance Support Ongoing evaluation Use

  14. Slide 14: Business Model

    Business Model License Fees BR A IN AGE® Place in up to 10,000 locations in North America (HCPs, psychiatric & neurology clinics, sport teams) Recurring Visits Programs offered up to 4 visits per year Pharma/Clinical Services Diagnostic tool for clinical studies Marketing Partners International dist

  15. Slide 15: 2025 Growth Plan

    2025 Growth Plan BR A IN AGE® International Expansion of Commercializing Novel BR AIN AGE® AI Molecular Hydrogen Grow provider sites, consumer Products and patient awareness Complement diagnostics platform and provide Establish BR AIN AGE® AI provider therapeutic options to clients Unlock new uses o

  16. Slide 16: Relationships

    Relationships DiagnaMed CSE: DMED | OTCQB: DGNMF

  17. Slide 17: Team

    Team Management Research Fabio Chianelli Dr. John Kounios, PhD Founder, Chairman, and CEO Principal Researcher - Brain Age Founder, CEO - PharmaTher Applied Cognitive & Brain Sciences Professor, Founder, President - Revive Thera Drexel University Jing Peng, CPA Dr. James E Galvin, M.D., M.P.H. Chief

  18. Slide 18: Financial Snapshot

    Financial Snapshot 80,052,640 2,000,000 Common Shares outstanding Stock Options 37,382,226 Common Shares are subject to escrow 1/10th released at: November 8, 2023, 2024, 2025 ~ 21% May 8, 2024, 2025, 2026 2/10th released at: Insider Ownership November 8, 2026

  19. Slide 19: Thank You

    THANK YOU DiagnaMed Holdings Corp. 82 Richmond Street East Toronto, ON M5C 1P1 t. 416-800-2684 e. info@diagnamed.com DiagnaMed CSE: DMED | OTCQB: DGNMF

DiagnaMed Holdings — Investor Presentation (November 2024) on 6ix